Mira Pharmaceuticals Inc
MIRA
Company Profile
Business description
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
Contact
1200 Brickell Avenue
Suite 1950 No. 1183
MiamiFL33133
USAT: +1 786 432-9792
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
2
Stocks News & Analysis
stocks
Nvidia earns upgrade as AI buildouts accelerate
Demand for AI infrastructure shows no signs of slowing.
stocks
Weekly earnings wrap: FMG, WDS, COL and more
A closer look at the final major results from August reporting season.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,294.30 | 32.90 | 0.36% |
| CAC 40 | 8,405.24 | 85.37 | 1.03% |
| DAX 40 | 26,566.35 | 199.11 | 0.76% |
| Dow JONES (US) | 53,688.34 | 118.90 | 0.22% |
| FTSE 100 | 10,815.52 | 22.98 | 0.21% |
| HKSE | 25,584.79 | 19.05 | 0.07% |
| NASDAQ | 26,634.48 | 93.13 | 0.35% |
| Nikkei 225 | 66,405.56 | 273.59 | 0.41% |
| NZX 50 Index | 13,768.18 | 111.87 | -0.81% |
| S&P 500 | 7,756.27 | 25.28 | 0.33% |
| S&P/ASX 200 | 9,092.30 | 41.00 | 0.45% |
| SSE Composite Index | 3,952.18 | 4.39 | -0.11% |